Skip to content

DIA proteomics combined with non targeted metabolomics to explore the pathogenesis of ovarian reserve dysfunction

DIA proteomics combined with non targeted metabolomics to explore the pathogenesis of ovarian reserve dysfunction

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076693
Enrollment
Unknown
Registered
2023-10-16
Start date
2023-07-06
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished ovarian reserve

Interventions

DOR Disease Group:None
Healthy control group:None

Sponsors

Dongguan Maternal and Child Health Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Female patients aged between 20 and 40 years old; (2) Conforming to the diagnostic criteria of Western and Chinese medicine for ovarian reserve dysfunction; (3) Those who have not received hormone therapy or other related treatments for the disease in the past three months; (4) Those who voluntarily sign an informed consent form voluntarily cooperate with treatment and have strong compliance.

Exclusion criteria

Exclusion criteria: (1) Primary or secondary amenorrhea or genital malformations caused by congenital reproductive organ developmental abnormalities or acquired organic lesions; (2) Patients with primary diseases such as cardiovascular and cerebrovascular diseases, Endocrine system diseases, hematopoietic system diseases and mental diseases such as anxiety and depression; (3) Known or suspected precancerous lesions or malignant tumors affected by sex hormones; (4) Suffering from severe liver, kidney, heart, and brain diseases; (5) Known or suspected pregnancy; (6) Participants in other clinical trials; (7) Patients who receive treatment with other exogenous hormones within 3 months; (8) Patients with a family history of ovarian dysfunction.

Design outcomes

Primary

MeasureTime frame
FSH;AMH;

Secondary

MeasureTime frame
E2;LH;

Countries

China

Contacts

Public ContactZhao Li

Dongguan Maternal and Child Health Care Hospital

778774975@qq.com+86 139 2552 3388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026